Repligen Initiates Phase 1b Trial of RG3039 for Spinal Muscular Atrophy Licensed From Families of SMA.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs PF 6687859 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
- 15 Jul 2013 New trial record